<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105555</url>
  </required_header>
  <id_info>
    <org_study_id>YTCR3419</org_study_id>
    <nct_id>NCT05105555</nct_id>
  </id_info>
  <brief_title>The e-BILD Study: Effects of E-cigarettes on Lung Health in Teenagers.</brief_title>
  <acronym>e-BILD</acronym>
  <official_title>The e-BILD Study: Effects of Electric Nicotine Delivery Systems (ENDS) on Pulmonary Health in Teenagers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic nicotine delivery systems (ENDS/e-cigarettes/vaping) are increasingly popular&#xD;
      among teenagers around the world. The safety and potential adverse effects of ENDS in this&#xD;
      population are largely unknown. While the aerosol, that users inhale, appears safe under&#xD;
      laboratory conditions, there are still open questions, which have not yet been assessed.&#xD;
      These cover (a) differences in exposure to chemicals (such as metabolites of Volatile Organic&#xD;
      Compounds (VOCs) and metabolites of Polycyclic Aromatic Hydrocarbons (PAHs)) between healthy&#xD;
      teenagers using ENDS and healthy teenagers not vaping, (b) effects of exposure to such&#xD;
      chemicals on the body (measured by lung health indicators: airway symptoms such as coughing;&#xD;
      lung function and lung structure tests; immune response of airway cells exposed to vapor;&#xD;
      markers of oxidative stress), and (c) the role of nicotine metabolism. It is unknown which&#xD;
      lung health indicator/s is/are most relevant to assess the effect of ENDS on lung health in&#xD;
      teenagers.&#xD;
&#xD;
      The primary hypothesis of this study is that there will be differences in exposure to&#xD;
      chemicals, resulting in more or more severe airway symptoms in vaping teenagers compared to&#xD;
      their non-vaping peers. While there might not yet exist any differences regarding lung&#xD;
      function or structure, we expect already visible effects of vaping on the local immune&#xD;
      response of primary cells isolated from airways in vaping teenagers as compared to non-vaping&#xD;
      peers.&#xD;
&#xD;
      In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth&#xD;
      cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping&#xD;
      controls.1 Vaping teenagers will be recruited independently from the BILD study through&#xD;
      advertisements and visits to Bernese schools. Both populations combined represent the study&#xD;
      population of the e-BILD study. All e-BILD study participants will undergo the same&#xD;
      investigations. While these are currently planned for once in a time (so-called&#xD;
      cross-sectional design) to compare results from non-vaping BILD study participants to&#xD;
      otherwise healthy but vaping teenagers, repeated measures might follow, depending on the&#xD;
      findings of the first phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of the respiratory symptom coughing with vaping status (validated by exposure markers)</measure>
    <time_frame>At baseline</time_frame>
    <description>Questions on frequency and intensity of coughing in past 12 months.&#xD;
Assessment of exposure markers (urinary concentrations of metabolites of VOCs (volatile organic compounds), urinary concentrations of metabolites of PAHs (Polycyclic aromatic hydrocarbons), urinary concentrations of urinary TSNA (Tobacco Specific Nitrosamines), urinary concentration of nicotine metabolites) to discriminate between vapers and non-vapers [Time Frame: at baseline]&#xD;
Urine sampling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of the respiratory symptom wheezing with vaping status (validated by exposure markers)</measure>
    <time_frame>At baseline</time_frame>
    <description>Questions on frequency and intensity of wheezing in past 12 months.&#xD;
Assessment of exposure markers (urinary concentrations of metabolites of VOCs (volatile organic compounds), urinary concentrations of metabolites of PAHs (Polycyclic aromatic hydrocarbons), urinary concentrations of urinary TSNA (Tobacco Specific Nitrosamines), urinary concentration of nicotine metabolites) to discriminate between vapers and non-vapers [Time Frame: at baseline]&#xD;
Urine sampling</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with lung function (spirometry) in healthy teenagers</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of lung function (spirometry)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with lung function (bodyplethysmography) in healthy teenagers</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of lung function (bodyplethysmography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of lung function (multiple breath washout) in healthy teenagers</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of lung function (multiple breath washout)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with airway inflammation (exhaled nitric oxide) in healthy teenagers.</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of levels of exhaled nitric oxide (eNO) measured by chemoluminescence analyzers in combination with ultrasound-based flow measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with lung structure (magnetic resonance imaging, MRI) in healthy teenagers.</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of regional lung perfusion and ventilation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with measures of oxidative stress in healthy teenagers.</measure>
    <time_frame>At baseline</time_frame>
    <description>Measurement of oxidative stress metabolites in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of validated vaping status with ex vivo immune response of nasal epithelial cells in healthy teenagers.</measure>
    <time_frame>At baseline</time_frame>
    <description>Assessment of nasal epithelial cell immune response collected by nasal brushing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Role of nicotine metabolism on lung health indicators.</measure>
    <time_frame>At baseline</time_frame>
    <description>Measurement of nicotine metabolites in urine and saliva.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vaping</condition>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a birth cohort of healthy term-born infants and their follow-up, will serve as healthy, non-vaping controls.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaping teenagers</arm_group_label>
    <description>Vaping teenagers will be recruited independently from the BILD study through advertisements and visits to Bernese schools.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Urine, Saliva, Nasal epithelial cells (obtained by nasal brushing)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In this study, participants of the Bern Basel Infant Lung Development (BILD) cohort, a&#xD;
        birth cohort of healthy term-born infants and their follow-up, will serve as healthy,&#xD;
        non-vaping controls. Vaping teenagers will be recruited independently from the BILD study&#xD;
        through advertisements and visits to Bernese schools. Both populations combined represent&#xD;
        the study population of the e-BILD study. All e-BILD study participants will undergo the&#xD;
        same investigations. While these are currently planned for once in a time (so-called&#xD;
        cross-sectional design) to compare results from non-vaping BILD study participants to&#xD;
        otherwise healthy but vaping teenagers, repeated measures might follow, depending on the&#xD;
        findings of the first phase.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent as documented by signature&#xD;
&#xD;
          -  BILD study participants: see inclusion criteria of BILD study (NCT04286464),&#xD;
             non-vaping&#xD;
&#xD;
          -  e-BILD: healthy, term-born, vaping at least weekly (might include healthy, vaping&#xD;
             participants from BILD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        â€¢ None, except for general exclusion criteria of BILD study (NCT04286464)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julian Jakob, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Primary Health Care BIHAM, Bern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reto Auer, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Primary Health Care BIHAM, Bern University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philipp Latzin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inselspital, Bern University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julian Jakob, MD</last_name>
    <phone>+41 31 684 58 70</phone>
    <email>julian.jakob@biham.unibe.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Insel, Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sybille Thommen</last_name>
      <phone>0041 31 632 94 31</phone>
      <email>sybille.thommen@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

